EDITION OF WED 4 NOV 2026
168 · WORLD

FDA tentatively approves first generic twice-yearly HIV prevention shot

publishers 23articles 26first reported 2 Nov, 14:45 UTCdeveloping since 2 Nov · 14 editions

The U.S. Food and Drug Administration has granted tentative approval to the first generic version of lenacapavir, a twice-yearly injectable medicine used to prevent HIV.

The generic was developed by India’s Dr. Reddy’s Laboratories under a voluntary licence from Gilead Sciences, which developed the original drug. The FDA decision was announced Monday by Dr. Reddy’s and global health initiative Unitaid.

Under a pricing agreement involving Unitaid, the Clinton Health Access Initiative and African research institute Wits RHI, the generic is expected to cost $40 per person annually and be offered in 120 low- and middle-income countries. The Independent reported that Zambia is expected to receive the first supplies.

Gilead’s version was approved by the FDA in June 2025 after clinical trials found it more than 99.9% effective at preventing HIV. It costs about $28,000 annually in the United States before insurance, according to reports. Unlike a vaccine, lenacapavir does not train the immune system; it is a form of pre-exposure prophylaxis that targets the protective shell around HIV’s genetic material.

Tentative FDA approval allows the generic to move closer to distribution through an accelerated pathway that relies partly on existing clinical data. Unitaid said more than 125,000 people in 10 early-adopter African countries have already begun receiving Gilead’s version.

HOW THIS STORY WAS MADE

Written from 8 articles, 2 with the publisher's own text; 7 independent newsrooms once syndicated copies count as one; this version written 24 h after the record first saw the story; the editor kept it as written.

Publishers
23
Source articles
26
Given to the writer
8, 2 with the article's own text
Independent newsrooms
7
This version written
24 h after the record first saw the story
Second model (editor)
kept as written
Publication gate
passed
Human review
none

WHAT THE EDITOR DID

The second model checked the writer's draft against the same sources and published it as written.

Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →

NAMED IN THE COVERAGE

OUTLETS CARRYING THE STORY, RUN BY RUN

0 13 26 3 Nov 4 Nov 5 Nov 6 Nov 7 Nov 8 Nov 9 Nov 10 Nov 11 Nov 12 Nov 13 Nov 14 Nov 15 Nov 3 Nov 06:17 UTC · FDA grants tentative approval to low-cost generic HIV prevention shot 3 Nov 12:19 UTC · FDA tentatively approves first generic twice-yearly HIV prevention injection 3 Nov 18:23 UTC · FDA tentatively approves first generic twice-yearly HIV prevention shot

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Nothing ran from the first third of the coverage to the last.

Entered the story later

  • Nothing new took hold after the first third.

HOW THIS STORY DEVELOPED: EVERY HEADLINE, EVERY OUTLET →